

F C Bidard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/446431/f-c-bidard-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120
papers

6,770
citations

42
h-index

80
g-index

139
ext. papers

8,040
ext. citations

6.8
avg, IF

5.52
L-index

#	Paper	IF	Citations
120	Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022 , 12, e055821	3	4
119	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , 2022 ,	5.7	4
118	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.. <i>Communications Biology</i> , 2022 , 5, 373	6.7	0
117	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021 , 13, 44	14.4	3
116	Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2021 , 23, 31	8.3	9
115	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3560-3570	8.8	4
114	Enhancer rewiring in tumors: an opportunity for therapeutic intervention. <i>Oncogene</i> , 2021 , 40, 3475-3493	9.2	4
113	HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. <i>ESMO Open</i> , 2021 , 6, 100154	6	4
112	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 34-41	13.4	30
111	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 443-452	9.7	8
110	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021 , 15, 1647-1666	7.9	28
109	Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. <i>Cancers</i> , 2021 , 13,	6.6	2
108	Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. <i>Breast Cancer Research</i> , 2021 , 23, 9	8.3	2
107	Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics). <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 1380-1392	5.1	1
106	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 115	7.8	9
105	Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. <i>European Journal of Cancer</i> , 2021 , 154, 128-137	7.5	5
104	Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. <i>British Journal of Cancer</i> , 2021 , 124, 1207-1213	8.7	5

103	Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa090	4.6	16
102	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. <i>Modern Pathology</i> , 2020 , 33, 2198-2207	9.8	9
101	COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. <i>Breast Cancer Research</i> , 2020 , 22, 55	8.3	58
100	High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies. <i>Clinical Chemistry</i> , 2020 , 66, 606-613	5.5	16
99	A single droplet digital PCR for ESR1 activating mutations detection in plasma. <i>Oncogene</i> , 2020 , 39, 2987-2995	16	16
98	Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. <i>BMC Cancer</i> , 2020 , 20, 352	4.8	11
97	Abstract 3390: Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial 2020 ,		2
96	Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer. <i>Journal of Breast Cancer</i> , 2020 , 23, 218-223	3	3
95	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020 , 23, 193-202	10.6	9
94	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020 , 66, 1093-1101	5.5	17
93	HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 86	8.3	8
92	Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy. <i>Breast Cancer Research</i> , 2020 , 22, 98	8.3	11
91	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. <i>Oncogene</i> , 2020 , 39, 487-500	3.2	38
90	ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. <i>Bioinformatics</i> , 2020 , 36, 3888-3889	7.2	2
89	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. <i>Cells</i> , 2019 , 8,	7.9	40
88	ESR1 mutations: a new biomarker in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 599-611	5.1	17
87	Circulating Tumor Cells in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz026	4.6	38
86	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	14

85	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4
84	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6
83	Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors?. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14135-e14135	2.2	1
82	Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature 2019 , 7, 317		8
81	Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. <i>Breast Cancer Research</i> , 2019 , 21, 121	8.3	25
80	Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 389-396	4	10
79	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
78	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 2109-2115	12.9	32
77	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 560-567	9.7	137
76	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5767-5771	12.9	38
75	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 639-650	19.4	108
74	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. <i>Clinical Chemistry</i> , 2018 , 64, 317-328	5.5	28
73	-Activating Mutations in Small Bowel Adenocarcinomas.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-9	3.6	1
72	Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions. <i>Journal of Visualized Experiments</i> , 2018 ,	1.6	3
71	Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. <i>Nature Communications</i> , 2018 , 9, 1866	17.4	65
70	Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018 , 4, 14	7.8	8
69	Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. <i>British Journal of Cancer</i> , 2017 , 116, 356-361	8.7	10
68	FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells. <i>Methods in Molecular Biology</i> , 2017 , 1547, 211-220	1.4	1

67	Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Clinical Chemistry</i> , 2017 , 63, 691-699	5.5	104
66	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 949-962	3.6	25
65	Circulating tumor cells: clinical validity and utility. <i>International Journal of Clinical Oncology</i> , 2017 , 22, 421-430	4.2	129
64	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. <i>Annals of Oncology</i> , 2017 , 28, 1996-2001	10.3	150
63	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. <i>Clinical Cancer Research</i> , 2017 , 23, 4402-4415	12.9	69
62	T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e138-e139	8.9	4
61	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. <i>European Journal of Cancer</i> , 2017 , 83, 185-193	7.5	17
60	Circulating tumor cell count and thrombosis in metastatic breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1981-1988	15.4	8
59	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017 , 28, 103-109	10.3	40
58	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy 2017 ,		5
57	HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. <i>International Journal of Cancer</i> , 2017 , 141, 1667-1670	7.5	19
56	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , 2016 , 10, 418-30	7.9	99
55	Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. <i>Molecular Oncology</i> , 2016 , 10, 481-93	7.9	61
54	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016 , 22, 4045-56	12.9	85
53	Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. <i>Oncologist</i> , 2016 , 21, 281-2	5.7	27
52	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2583-93	12.9	222
51	ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016 , 7, 73337-73346	3.3	24
50	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). <i>Annals of Oncology</i> , 2016 , 27, 812-8	10.3	149

49	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	72
48	High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. <i>Lab on A Chip</i> , 2015 , 15, 2090-101	7.2	50
47	Clinical utility of circulating tumor cells in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1622	2.2	19
46	Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. <i>Cancer Letters</i> , 2015 , 360, 213-8	9.9	35
45	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. <i>Annals of Oncology</i> , 2015 , 26, 1704-9	10.3	16
44	Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. <i>International Journal of Cancer</i> , 2015 , 136, 2158-65	7.5	115
43	Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. <i>Clinical Cancer Research</i> , 2015 , 21, 1298-304	12.9	43
42	FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool. <i>Lab on A Chip</i> , 2015 , 15, 811-22	7.2	25
41	Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. <i>Molecular Oncology</i> , 2015 , 9, 783-90	7.9	200
40	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. <i>PLoS ONE</i> , 2015 , 10, e0144359	3.7	18
39	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 406-14	21.7	566
38	Trends in cancer-targeted antibody-drug conjugates. <i>Targeted Oncology</i> , 2014 , 9, 1-8	5	6
37	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. <i>Annals of Oncology</i> , 2014 , 25, 1729-1735	10.3	258
36	Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. <i>Molecular Oncology</i> , 2014 , 8, 1588-602	7.9	38
35	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. <i>Molecular Oncology</i> , 2014 , 8, 150-8	7.9	34
34	Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. <i>Cancer Research</i> , 2014 , 74, 2946-2961	10.1	14
33	A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging. <i>Biomicrofluidics</i> , 2014 , 8, 024109	3.2	17
32	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, R43	8.3	41

31	Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. <i>International Journal of Cancer</i> , 2014 , 134, 1207-13	7.5	129
30	Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. <i>Annals of Oncology</i> , 2013 , 24, 2999-3004	10.3	36
29	Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. <i>Cancer and Metastasis Reviews</i> , 2013 , 32, 179-88	9.6	195
28	Translating metastasis-related biomarkers to the clinic--progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 169-79	19.4	35
27	Going with the flow: from circulating tumor cells to DNA. <i>Science Translational Medicine</i> , 2013 , 5, 207ps147.5	14.7.5	90
26	Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. <i>Clinical Cancer Research</i> , 2013 , 19, 1596-602	12.9	42
25	Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. <i>International Journal of Breast Cancer</i> , 2013 , 2013, 130470	2.3	45
24	Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 1231-8	10.3	53
23	Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. <i>Annals of Oncology</i> , 2013 , 24, 2057-61	10.3	139
22	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013 , 8, e67148	3.7	68
21	Disseminated and circulating tumor cells in gastrointestinal oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 82, 103-15	7	27
20	Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. <i>Breast Cancer Research</i> , 2012 , 14, R29	8.3	62
19	Microfluidic: an innovative tool for efficient cell sorting. <i>Methods</i> , 2012 , 57, 297-307	4.6	110
18	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology, The</i> , 2012 , 13, 375-84	21.7	134
17	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 618-624	10.3	213
16	Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. <i>Clinical Cancer Research</i> , 2012 , 18, 3934-41	12.9	63
15	Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification. <i>PLoS ONE</i> , 2012 , 7, e47390	3.7	15
14	Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1458-1459	10.3	11

13	Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. <i>Annals of Oncology</i> , 2010 , 21, 729-733	10.3	193
12	Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 14524-9	11.5	260
11	Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. <i>Annals of Oncology</i> , 2010 , 21, 1765-1771	10.3	116
10	Survival of breast cancer patients with meningeal carcinomatosis. <i>Annals of Oncology</i> , 2010 , 21, 2183-2187	7.3	116
9	Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. <i>Annals of Oncology</i> , 2009 , 20, 1836-41	10.3	33
8	Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2009 , 35, 582-9	14.4	10
7	Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma. <i>European Journal of Cancer</i> , 2009 , 45, 1979-86	7.5	7
6	Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. <i>Clinical Cancer Research</i> , 2008 , 14, 7004-10	12.9	305
5	Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. <i>Journal of Clinical Pathology</i> , 2008 , 61, 570-6	3.9	49
4	Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. <i>Annals of Oncology</i> , 2008 , 19, 496-500	10.3	95
3	Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. <i>Clinical Cancer Research</i> , 2008 , 14, 3306-11	12.9	115
2	A "class action" against the microenvironment: do cancer cells cooperate in metastasis?. <i>Cancer and Metastasis Reviews</i> , 2008 , 27, 5-10	9.6	105
1	Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. <i>Clinical and Experimental Metastasis</i> , 2008 , 25, 871-5	4.7	13